Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality–free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients
European Urology Focus · 2023-09 · 9 (5) · 799-806
DOI: 10.1016/j.euf.2023.03.014 ↗Kurz gefasst
Kommentar in der Zeitschrift European Urology Focus, 2023-09. Verfasst von Mattia Luca Piccinelli und 21 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urolo…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Accurate prediction of cancer control outcomes in renal cell carcinoma (RCC) patients is important for counselling, follow-up planning, and selection of appropriate adjuvant trial designs. OBJECTIVE: To develop and externally validate a novel contemporary population-based model for predicting cancer-specific mortality-free survival (CSM-FS) in surgically treated papillary RCC (papRCC) patients and to compare it with established risk categories (Leibovich 2018). DESIGN, SETTING, AND PARTICIPANTS: Within the Surveillance, Epidemiology, and End Results database (2004-2019), we identified surgically treated papRCC patients (n = 3978). The population was randomly divided into development (50%, n = 1989) and external validation (50%, n = 1989) cohorts. Of the external validation cohort, 97% (n = 1930) of patients were included in a head-to-head comparison of the Leibovich 2018 risk categories addressing nonmetastatic patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariable Cox regression models tested the statistical significance in the prediction of CSM-FS. The most parsimonious model with the best validation metrics was selected as the multivariable nomogram. Accuracy, calibration, and decision curve analyses (DCAs) tested the Cox regression-based nomogram, as well as the Leibovich 2018 risk categories in the external validation cohort. RESULTS AND LIMITATIONS: Age at diagnosis, grade, T stage, N stage, and M stage qualified for inclusion in the novel nomogram. In external validation, the accuracy of the novel nomogram was 0.83 at 5 yr and 0.80 at 10 yr. In nonmetastatic patients, 5- and 10-yr accuracy of the novel nomogram was 0.77 and 0.76, respectively. Conversely, 5- and 10-yr accuracy of the Leibovich 2018 risk categories was 0.70 and 0.66, respectively. The novel nomogram exhibited smaller departures from ideal predictions in calibration plots and higher net benefit in DCAs, when it was compared with the Leibovich 2018 risk categories. Limitations include the retrospective nature of the study, absence of a central pathological review, and inclusion of only North American patients. CONCLUSIONS: The novel nomogram may represent a valuable clinical aid, when papRCC CSM-FS predictions are required. PATIENT SUMMARY: We developed an accurate tool to predict death due to papillary kidney cancer in a North American population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy; Universit…
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IR…
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, IRCCS Policlinico San Martino, Genova, Italy; Department of Surgic…
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main…
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Ge…
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Neurosciences, Science of Reproduction and Odontostomatology, University of…
Zitieren
APA
Piccinelli, M. L., Barletta, F., Tappero, S., Cano Garcia, C., Incesu, R. B., Morra, S., Scheipner, L., Tian, Z., Luzzago, S., Mistretta, F. A., Ferro, M., Saad, F., Shariat, S. F., Ahyai, S., Longo, N., Tilki, D., Chun, F. K. H., Terrone, C., Briganti, A., …, & Karakiewicz, P. I. (2023). Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality–free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients. European Urology Focus, 9(5), 799-806. https://doi.org/10.1016/j.euf.2023.03.014
Vancouver
Piccinelli ML, Barletta F, Tappero S, Cano Garcia C, Incesu RB, Morra S, et al. Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality–free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients. European Urology Focus. 2023;9(5):799-806. doi:10.1016/j.euf.2023.03.014
BibTeX
@article{Piccinelli2023,
author = {Piccinelli, Mattia Luca and Barletta, Francesco and Tappero, Stefano and Cano Garcia, Cristina and Incesu, Reha-Baris and Morra, Simone and Scheipner, Lukas and Tian, Zhe and Luzzago, Stefano and Mistretta, Francesco A and Ferro, Matteo and Saad, Fred and Shariat, Shahrokh F and Ahyai, Sascha and Longo, Nicola and Tilki, Derya and Chun, Felix K H and Terrone, Carlo and Briganti, Alberto and de Cobelli, Ottavio and Musi, Gennaro and Karakiewicz, Pierre I},
title = {Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality–free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients},
journal = {European Urology Focus},
year = {2023},
volume = {9},
number = {5},
pages = {799--806},
doi = {10.1016/j.euf.2023.03.014}
}
EUVIMED